The Current Ratio as of December 2024 (TTM) for Aurinia Pharmaceuticals Inc. (AUPH) is 5.60

According to Aurinia Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 5.60. This represents a change of 1.70% compared to the average of 5.51 of the last 4 quarters.

Aurinia Pharmaceuticals Inc. (AUPH) Historical Current Ratio (quarterly & annually)

How has AUPH Current Ratio performed in the past?

The mean historical Current Ratio of Aurinia Pharmaceuticals Inc. over the last ten years is 13.02. The current 5.60 Current Ratio has changed 4.20% with respect to the historical average. Over the past ten years (40 quarters), AUPH's Current Ratio was at its highest in in the June 2017 quarter at 53.07. The Current Ratio was at its lowest in in the March 2016 quarter at 3.05.

Aurinia Pharmaceuticals Inc. (AUPH) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Aurinia Pharmaceuticals Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Aurinia Pharmaceuticals Inc. (AUPH) Average Current Ratio

How has AUPH Current Ratio performed in the past?

The current Current Ratio of Aurinia Pharmaceuticals Inc. (AUPH) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Aurinia Pharmaceuticals Inc. (AUPH) Current Ratio vs. Peers

How is AUPH’s Current Ratio compared to its peers?

Aurinia Pharmaceuticals Inc.’s Current Ratio is less than Viking Therapeutics, Inc. (36.47), greater than Axsome Therapeutics, Inc. (2.44), less than Madrigal Pharmaceuticals, Inc. (5.98), greater than ImmunoGen, Inc. (5.47), greater than Seres Therapeutics, Inc. (1.12), greater than Exelixis, Inc. (3.93), greater than TG Therapeutics, Inc. (4.59), greater than BioXcel Therapeutics, Inc. (1.87), greater than Sarepta Therapeutics, Inc. (3.84), greater than Hepion Pharmaceuticals, Inc. (1.30), greater than PTC Therapeutics, Inc. (2.10), less than Intercept Pharmaceuticals, Inc. (0), greater than Terns Pharmaceuticals, Inc. (4.22), less than Akero Therapeutics, Inc. (32.99), less than Reata Pharmaceuticals, Inc. (17.25), less than null (6.75),

Build a custom stock screener for Aurinia Pharmaceuticals Inc. (AUPH) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aurinia Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aurinia Pharmaceuticals Inc. (AUPH) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aurinia Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.